Neurocrine's pediatric phase 3 data are missing piece of puzzle for hyperplasia drug submission

A month after Neurocrine Biosciences’ drug crinecerfont renewed analysts’ hopes of its blockbuster potential by acing a phase 3 study in adults with hyperplasia, the therapy has now scored another win in the pediatric version of the trial.